Sign in
Taking people in United StatesPhase 1

Tests ruxolitinib with chemotherapy for Ph-like acute lymphoblastic leukemia in young adults

Tests adding ruxolitinib to chemotherapy in young adults with new Ph-like leukemia.

Key facts

Who runs it
University of Chicago
Where
Chicago and Dallas, United StatesSee the 2 sites
Trial code
Registry title
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
28 May 2019
Expected to end
5 Sept 2027
Type of study
Interventional
Treatments tested
  • Ruxolitinib
  • Cyclophosphamide
  • Cytarabine
  • Mercaptopurine
  • Vincristine
  • Pegaspargase
  • Rituximab
  • Methotrexate (Intrathecal Administration)
  • Methotrexate (Intravenous Administration)
  • Dexamethasone
  • Doxorubicin
  • Thioguanine
  • Methotrexate Oral Product
Record updated
29 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adolescents and young adults with newly diagnosed Ph-like B-cell acute lymphoblastic leukemia who have a JAK-targetable gene change and have finished a 4-drug induction treatment.

Age
18 years up to 39 years (at least 18 and under 40).
Sex
All sexes can join.
Disease stage
Newly diagnosed B-precursor acute lymphoblastic leukemia (ALL), with a "Ph-like" signature.
Earlier treatment
Must have completed a 4-drug induction regimen with intrathecal chemotherapy before starting ruxolitinib. No other treatment for leukemia except emergency treatment (corticosteroids or hydroxyurea).
Biomarker or test result
Ph-like signature on a low density micro-array (LDA) card, plus a JAK-targetable gene change: CRLF2 rearranged, JAK2 or EPOR fusions, or other JAK pathway changes such as SH2B3 deletions or IL7RA mutations.

Main reasons for not taking part

  • Pregnant women
  • Down Syndrome
  • Burkitt type leukemia or Ph+ ALL at diagnosis
  • Another active cancer (other than non-melanoma skin cancer)
  • Uncontrolled other illness, such as active infection or heart failure

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis of precursor B ALL. This includes an institutional immunophenotyping report that is to assign B-lineage or T-lineage
  • "Ph-like" signature, as determined by low density micro-array (LDA) card
  • Jak-targetable genetic signature as defined by any of the following:; Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type); JAK2 or erythropoietin receptor (EPOR) fusions; Other JAK pathway alterations at the discretion of the principle investigator including, but not limited to:
  • SH2B adaptor protein 3 (SH2B3) deletions
  • Interleukin-7 receptor subunit alpha (IL7RA) mutations
  • Prior therapy; Prior to starting ruxolitinib, patients must have completed a 4-drug induction regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as per the institutional standard of care. Recommended induction treatment is outlined in Section 5.1.2; No additional prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys. When indicated, leukapheresis or exchange transfusion is recommended to reduce the white blood cell count (WBC); Screening may occur at any point prior to or during induction therapy
  • Age ≥ 18 years and < 40 years. Because this is specifically a study of the adolescent and young adult population and no adverse event data are currently available on the use of this pediatric-based chemotherapy regimen in patients ≥ 40 years of age, older adults are excluded from this study, but may be eligible for future trials
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥ 60%)
  • Platelet count > 25,000/uL
  • Patients must have normal organ function as defined below:; total bilirubin ≤ 2 mg/dL; aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 × institutional upper limit of normal; creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Because the therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Patients who are receiving any other investigational agent
  • Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone, and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is minimal inhibition of CYP3A4 [36] and therefore fluconazole is not prohibited on this trial and no dose modifications should be made in the presence of fluconazole; Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Pregnant women are excluded from this study because ruxolitinib is a class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Down Syndrome due to the likelihood of excessive toxicity resulting. These patients should be treated in consultation with a pediatric oncologist
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years
  • Burkitt type leukemia
  • Ph+ ALL at time of diagnosis

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 39 years old?

Where in United States

  • University of Chicago Medical CenterChicago, United StatesContact: Howie WeinerTaking people
  • The University of Texas Southwestern Medical CenterDallas, United StatesContact: Clinical Trials OfficeNo longer taking part

About the trial

What the trial wants to find out

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

The group in the trial

  • RuxolitinibTreatment being tested

    Participants will receive ruxolitinib in addition to standard chemotherapy. Standard Chemotherapy Consists of: * Remission consolidation therapy (lasting 8 weeks) * Interim Maintenance (lasting 8 weeks) * Delayed Intensification (lasting 8 weeks * Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years) Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care.

    Treatment: Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, and Methotrexate Oral Product

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Plain-language title
Tests ruxolitinib with chemotherapy for Ph-like acute lymphoblastic leukemia in young adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT03571321, who can take part
Record updated
29 June 2026